Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 9/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 9/20 | 0.36 |
| ▸ | SLC2A4 | P14672 | 9/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | CPT1A | P50416 | 2/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 3/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089945 | 0.95 | KLKB1 (0.35) | SLC2A1SLC2A3SLC2A4PPARGELANE | |
| SCHEMBL10089980 | 0.94 | IDH1 (0.36) | SLC2A1SLC2A3SLC2A4NR1I2PPARG | |
| SCHEMBL10089859 | 0.93 | SLC2A1 (0.37) | SLC2A1SLC2A3SLC2A4ELANESLC2A2 | |
| SCHEMBL10089975 | 0.92 | SLC2A1 (0.35) | SLC2A1SLC2A3SLC2A4NR1I2PPARG | |
| SCHEMBL10090041 | 0.90 | GPR6 (0.34) | SLC2A1SLC2A3SLC2A4GPR6 | |
| SCHEMBL10089953 | 0.90 | RIPK1 (0.37) | SLC2A1SLC2A3SLC2A4PPARG | |
| SCHEMBL10089908 | 0.89 | KLKB1 (0.35) | SLC2A1SLC2A3SLC2A4PPARGELANE | |
| SCHEMBL10090042 | 0.88 | GPR6 (0.35) | SLC2A1SLC2A3SLC2A4ELANESLC2A2 | |
| SCHEMBL13085225 | 0.87 | SLC2A1 (0.37) | SLC2A1SLC2A3SLC2A4ELANESLC2A2 | |
| SCHEMBL10089857 | 0.87 | LMNA (0.39) | SLC2A1SLC2A3SLC2A4SLC2A2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | SLC2A1 3782/4885SLC2A3 3762/4885SLC2A4 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.